China Pharma Holdings, Inc. (CPHI) |
|
0.1026 -0.002 (-2.19%)
|
01-27 16:00 |
|
Open: |
0.105 |
Pre. Close: |
0.1049 |
|
High:
|
0.1079 |
Low:
|
0.102 |
|
Volume:
|
1,205,907 |
Market Cap:
|
5(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:43:32 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 0.14 One year: 0.16 |
| Support: |
Support1: 0.09 Support2: 0.07 |
| Resistance: |
Resistance1: 0.11 Resistance2: 0.14 |
| Pivot: |
0.1  |
| Moving Average: |
MA(5): 0.1 MA(20): 0.1
MA(100): 0.12 MA(250): 0.22 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1  |
| Stochastic oscillator: |
%K(14,3): 43.8 %D(3): 63 |
| RSI: |
RSI(14): 46.3 |
| 52-week: |
High: 0.52 Low: 0.07 |
| Average Vol(K): |
3-Month: 2,575 (K) 10-Days: 1,583 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CPHI ] has closed above bottom band by 27.2%. Bollinger Bands are 45.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.11 - 0.11 |
0.11 - 0.11 |
|
Low:
|
0.1 - 0.1 |
0.1 - 0.1 |
|
Close:
|
0.1 - 0.1 |
0.1 - 0.1 |
|
Company Description |
|
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China. |
Headline News |
Mon, 23 Jan 2023
Aptar Pharma Wins Two InnoPack 2022 China Awards - Aptar
Mon, 02 Jan 2023
Predicting Pharma's Future - Pharmaceutical Technology Magazine
Thu, 03 Nov 2022
[From the Scene] Korean firms' presence at CPhI triples this year - The Korea Herald
Wed, 02 Nov 2022
CPHI 2022 Award Winners Announced - Pharmaceutical Technology Magazine
Tue, 01 Nov 2022
CPHI report predicts funding overhang to drive contract services - European Pharmaceutical Review
Thu, 27 Oct 2022
Prestige Biopharma Group to Exhibit at CPhI Frankfurt 2022 - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
47 (M) |
| Shares Float |
24 (M) |
|
% Held by Insiders
|
48.8 (%) |
|
% Held by Institutions
|
2.7 (%) |
|
Shares Short
|
284 (K) |
|
Shares Short P.Month
|
587 (K) |
Stock Financials |
|
EPS
|
-0.08 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0.41 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.14 |
|
Profit Margin (%)
|
-37.5 |
|
Operating Margin (%)
|
-34.3 |
|
Return on Assets (ttm)
|
-10.6 |
|
Return on Equity (ttm)
|
-49.4 |
|
Qtrly Rev. Growth
|
-17.7 |
|
Gross Profit (p.s.)
|
0.04 |
|
Sales Per Share
|
0.2 |
|
EBITDA (p.s.)
|
-0.01 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-1 (M) |
Stock Valuations |
|
PE Ratio
|
-1.29 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.73 |
|
Price to Sales
|
0.5 |
|
Price to Cash Flow
|
17.15 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
